 He concluded that the initiative as initially established was a "huge waste of money" and a "major policy error".The researchers studied the 47 treatments that were being funded by January 2015, of which only 18% met internationally recognised criteria for being deemed clinically beneficial.For those drugs where there was some evidence of benefit, the average was an extra 3.2 months of survival.